Keywords
IBS
Dementia
All-cause dementia
Alzheimer’s
Data Availability Statement
The data generated in this study are available upon request from the corresponding author.
How to Cite
Abstract
Background: Numerous gastrointestinal (GI) diseases have been linked to an increased risk of dementia. Irritable bowel syndrome (IBS) is a prevalent GI disorder; however, existing studies investigating its association with dementia have reported mixed findings, and no prior meta-analysis has synthesized the available evidence.
Methods: A comprehensive search of MEDLINE (via PubMed), Scopus, and Web of Science was conducted in August 2025, with no language restrictions, to identify observational studies comparing the risk of all-cause dementia and dementia subtypes (e.g., Alzheimer's disease (AD) in individuals with and without IBS. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using the DerSimonian–Laird random-effects model. The certainty of evidence was assessed using the GRADE approach.
Results: More than 750,000 participants were included from three cohort and two case-control studies. The pooled analysis showed that IBS was associated with significantly higher odds of all-cause dementia (OR = 1.22; 95% CI: 1.13–1.31; p < 0.00001; I² = 26%), with the overall certainty of evidence rated as high. The association remained robust across all sensitivity analyses. IBS was also significantly associated with higher odds of AD (OR = 1.27; 95% CI: 1.08–1.50; p = 0.005; I² = 64%), with the certainty of evidence rated as low.
Conclusion: Our findings consistently suggest that IBS is associated with higher rates of dementia outcomes; however, this association is derived from observational data and does not establish causality. Further well-designed prospective studies are needed to clarify the nature of this relationship.
References
1. Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al. Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2024;5(6):e406–21. PMID: 38824956; PMCID: PMC11139659. https://doi.org/10.1016/S2666-7568(24)00061-8
2. Payton NM, Marseglia A, Grande G, Fratiglioni L, Kivipelto M, Backman L, et al. Trajectories of cognitive decline and dementia development: A 12-year longitudinal study. Alzheimers Dement. 2023;19(3):857–67. PMID: 35715929. https://doi.org/10.1002/alz.12704
3. White L, Fishman P, Basu A, Crane PK, Larson EB, Coe NB. Medicare expenditures attributable to dementia. Health Serv Res. 2019;54(4):773–81. PMID: 30868557; PMCID: PMC6606539. https://doi.org/10.1111/1475-6773.13134
4. Helal MM, Almosilhy NA, Hamam NG, Abdelbaset MAA, Shelbaya AN, Musse HAY, et al. Sacubitril/Valsartan Reduces the Risk of All-Cause Dementia in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Drugs Aging. 2025;42(10):907–20. PMID: 40728824. https://doi.org/10.1007/s40266-025-01233-1
5. Megur A, Baltriukiene D, Bukelskiene V, Burokas A. The Microbiota-Gut-Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame? Nutrients. 2020;13(1). PMID: 33374235; PMCID: PMC7824474. https://doi.org/10.3390/nu13010037
6. Stadlbauer V, Engertsberger L, Komarova I, Feldbacher N, Leber B, Pichler G, et al. Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study. BMC Geriatr. 2020;20(1):248. PMID: 32690030; PMCID: PMC7372911. https://doi.org/10.1186/s12877-020-01644-2
7. Qian XH, Song XX, Liu XL, Chen SD, Tang HD. Inflammatory pathways in Alzheimer’s disease mediated by gut microbiota. Ageing Res Rev. 2021;68:101317. PMID: 33711509. https://doi.org/10.1016/j.arr.2021.101317
8. Newton JL, Hollingsworth KG, Taylor R, El-Sharkawy AM, Khan ZU, Pearce R, et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology. 2008;48(2):541–9. PMID: 18563843. https://doi.org/10.1002/hep.22371
9. Shang Y, Widman L, Hagstrom H. Nonalcoholic Fatty Liver Disease and Risk of Dementia: A Population-Based Cohort Study. Neurology. 2022;99(6):e574–82. PMID: 35831178; PMCID: PMC9442617. https://doi.org/10.1212/WNL.0000000000200853
10. Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, et al. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. Gut. 2021;70(1):85–91. PMID: 32576641. https://doi.org/10.1136/gutjnl-2020-320789
11. Huang KY, Wang FY, Lv M, Ma XX, Tang XD, Lv L. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol. 2023;29(26):4120–35. PMID: 37475846; PMCID: PMC10354571. https://doi.org/10.3748/wjg.v29.i26.4120
12. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–21.e4. PMID: 22426087. https://doi.org/10.1016/j.cgh.2012.02.029
13. Chen CH, Lin CL, Kao CH. Irritable Bowel Syndrome Is Associated with an Increased Risk of Dementia: A Nationwide Population-Based Study. PLoS One. 2016;11(1):e0144589. PMID: 26731277; PMCID: PMC4701489. https://doi.org/10.1371/journal.pone.0144589
14. Konings B, Villatoro L, Van den Eynde J, Barahona G, Burns R, McKnight M, et al. Gastrointestinal syndromes preceding a diagnosis of Parkinson’s disease: testing Braak’s hypothesis using a nationwide database for comparison with Alzheimer’s disease and cerebrovascular diseases. Gut. 2023;72(11):2103–11. PMID: 37620120. https://doi.org/10.1136/gutjnl-2023-329685
15. Tung H, Lin CH, Chen YM, Lee WJ, Chien LS, Sun TH, et al. Utilizing apolipoprotein E genotypes and associated comorbidities for the assessment of the risk for dementia. Front Aging Neurosci. 2022;14:927656. PMID: 36578446; PMCID: PMC9790994. https://doi.org/10.3389/fnagi.2022.927656
16. Yeh HW, Chien WC, Chung CH, Hu JM, Tzeng NS. Risk of psychiatric disorders in irritable bowel syndrome—A nationwide, population-based, cohort study. Int J Clin Pract. 2018;72(7):e13212. PMID: 29920876. https://doi.org/10.1111/ijcp.13212
17. Yuan S, Dan L, Zhang Y, Wu J, Zhao J, Kivipelto M, et al. Digestive System Diseases, Genetic Risk, and Incident Dementia: A Prospective Cohort Study. Am J Prev Med. 2024;66(3):516–25. PMID: 37918457. https://doi.org/10.1016/j.amepre.2023.10.017
18. Lu LY, Wu MY, Kao YS, Hung CH. Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies. Clin Mol Hepatol. 2022;28(4):931–2. PMID: 36064305; PMCID: PMC9597230. https://doi.org/10.3350/cmh.2022.0259
19. Liu N, Wang Y, He L, Sun J, Wang X, Li H. Inflammatory bowel disease and risk of dementia: An updated meta-analysis. Front Aging Neurosci. 2022;14:962681. PMID: 36275009; PMCID: PMC9581261. https://doi.org/10.3389/fnagi.2022.962681
20. Peng TR, Lin HH, Yang LJ, Huang YY, Wu TW, Chao YC. The impact of inflammatory bowel disease on dementia risk: a current systematic review and meta-analysis. Sci Rep. 2025;15(1):12852. PMID: 40229330; PMCID: PMC11997168. https://doi.org/10.1038/s41598-025-96331-w
21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. PMID: 33789826. https://doi.org/10.1016/j.ijsu.2021.105906
22. Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24(1):243. PMID: 39425031; PMCID: PMC11487830. https://doi.org/10.1186/s12874-024-02356-6
23. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. ResearchGate. Available from: https://www.researchgate.net/publication/261773681_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_the_Quality_of_Non-Randomized_Studies_in_Meta-Analysis
24. Cummings P. The relative merits of risk ratios and odds ratios. Arch Pediatr Adolesc Med. 2009;163(5):438–45. PMID: 19414690. https://doi.org/10.1001/archpediatrics.2009.31
25. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5, updated August 2024. Cochrane; 2024.
26. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55–79. PMID: 26332144; PMCID: PMC4950030. https://doi.org/10.1002/jrsm.1164
27. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–29. PMID: 11106885. https://doi.org/10.1016/S0895-4356(00)00242-0
28. Prasad M. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clinical Epidemiology and Global Health. 2024;25. https://doi.org/10.1016/j.cegh.2023.101484
29. Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62–70. PMID: 31982539. https://doi.org/10.1016/j.jclinepi.2019.12.023
30. Amin HS, Irfan F, Karim SI, Almeshari SM, Aldosari KA, Alzahrani AM, et al. The prevalence of irritable bowel syndrome among Saudi population in Riyadh by use of Rome IV criteria and self-reported dietary restriction. Saudi J Gastroenterol. 2021;27(6):383–90. https://doi.org/10.4103/sjg.sjg_43_21
31. Devanarayana NM, Adhikari C, Pannala W, Rajindrajith S. Prevalence of functional gastrointestinal diseases in a cohort of Sri Lankan adolescents: comparison between Rome II and Rome III criteria. J Trop Pediatr. 2011;57(1):34–9. PMID: 20525779. https://doi.org/10.1093/tropej/fmq039
32. Lopez-Colombo A, Morgan D, Bravo-Gonzalez D, Montiel-Jarquin A, Mendez-Martinez S, Schmulson M. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. Gastroenterol Res Pract. 2012;2012:606174. PMID: 22474443; PMCID: PMC3313569. https://doi.org/10.1155/2012/606174
33. Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. Frontline Gastroenterol. 2014;5(4):266–71. PMID: 28839783; PMCID: PMC5369735. https://doi.org/10.1136/flgastro-2013-100426
34. Smiliotopoulos T, Zampelas A, Houliaras G, Sgouros SN, Michas G, Bamias G, et al. Association of fructose consumption with prevalence of functional gastrointestinal disorders manifestations: results from Hellenic National Nutrition and Health Survey (HNNHS). Br J Nutr. 2023;130(11):1961–72. PMID: 37197939; PMCID: PMC10630147. https://doi.org/10.1017/S0007114523001198
35. Huang KY, Yu ZZ, Tu JJ, Tang XY, Huang JM, Lu TM, et al. Positive association between constipation and mild cognitive impairment in elders: A cross-sectional study. Medicine (Baltimore). 2024;103(40):e39943. PMID: 39465768; PMCID: PMC11460931. https://doi.org/10.1097/MD.0000000000039943
36. Wang F, Fei M, Hu WZ, Wang XD, Liu S, Zeng Y, et al. Prevalence of Constipation in Elderly and Its Association With Dementia and Mild Cognitive Impairment: A Cross-Sectional Study. Front Neurosci. 2021;15:821654. PMID: 35140587; PMCID: PMC8819140. https://doi.org/10.3389/fnins.2021.821654
37. Adewuyi EO, O’Brien EK, Porter T, Laws SM. Relationship of Cognition and Alzheimer’s Disease with Gastrointestinal Tract Disorders: A Large-Scale Genetic Overlap and Mendelian Randomisation Analysis. Int J Mol Sci. 2022;23(24). PMID: 36555837; PMCID: PMC9784325. https://doi.org/10.3390/ijms232416199
38. Berrill JW, Gallacher J, Hood K, Green JT, Matthews SB, Campbell AK, et al. An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease. Neurogastroenterol Motil. 2013;25(11):918–e704. PMID: 23981191. https://doi.org/10.1111/nmo.12219
39. Ding W, Chen L, Pei B, Gao D, Xia J, Li X, et al. Causal link between mental disorders and gastrointestinal diseases: a Mendelian randomization study. Front Endocrinol (Lausanne). 2025;16:1288619. PMID: 40331137; PMCID: PMC12052545. https://doi.org/10.3389/fendo.2025.1288619
40. Rijnhart JJM, Rabbers A, Rizzuto S, Howard AM, Valente MJ. An umbrella review reveals that control variables are rarely considered as a source of heterogeneity in systematic reviews of observational studies. J Clin Epidemiol. 2025;184:111826. PMID: 40368221. https://doi.org/10.1016/j.jclinepi.2025.111826
41. Cleveland ML. Preserving Cognition, Preventing Dementia. Clin Geriatr Med. 2020;36(4):585–99. PMID: 33010896. https://doi.org/10.1016/j.cger.2020.06.003
42. Tari AR, Walker TL, Huuha AM, Sando SB, Wisloff U. Neuroprotective mechanisms of exercise and the importance of fitness for healthy brain ageing. Lancet. 2025;405(10484):1093–118. PMID: 40157803. https://doi.org/10.1016/S0140-6736(25)00184-9
43. Daulatzai MA. Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. Neurochem Res. 2014;39(4):624–44. PMID: 24590859. https://doi.org/10.1007/s11064-014-1266-6
44. Mayer EA, Ryu HJ, Bhatt RR. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023;28(4):1451–65. PMID: 36732586; PMCID: PMC10208985. https://doi.org/10.1038/s41380-023-01972-w
45. Raskov H, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes. 2016;7(5):365–83. PMID: 27472486; PMCID: PMC5046167. https://doi.org/10.1080/19490976.2016.1218585
46. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation. 2012;9:151. PMID: 22747753; PMCID: PMC3483167. https://doi.org/10.1186/1742-2094-9-151
47. Warren A, Nyavor Y, Zarabian N, Mahoney A, Frame LA. The microbiota-gut-brain-immune interface in the pathogenesis of neuroinflammatory diseases: a narrative review of the emerging literature. Front Immunol. 2024;15:1365673. PMID: 38817603; PMCID: PMC11137262. https://doi.org/10.3389/fimmu.2024.1365673
48. Buckley MM, O’Mahony SM, O’Malley D. Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome. World J Gastroenterol. 2014;20(27):8846–58. PMID: 25083058; PMCID: PMC4112880. https://doi.org/10.3748/wjg.v20.i27.8846
49. Ishioh M, Nozu T, Okumura T. Brain Neuropeptides, Neuroinflammation, and Irritable Bowel Syndrome. Digestion. 2024;105(1):34–9. PMID: 37673052. https://doi.org/10.1159/000533275
50. Li B, He Y, Ma J, Huang P, Du J, Cao L, et al. Mild cognitive impairment has similar alterations as Alzheimer’s disease in gut microbiota. Alzheimers Dement. 2019;15(10):1357–66. PMID: 31434623. https://doi.org/10.1016/j.jalz.2019.07.002
51. Zhong SR, Kuang Q, Zhang F, Chen B, Zhong ZG. Functional roles of the microbiota-gut-brain axis in Alzheimer’s disease: Implications of gut microbiota-targeted therapy. Transl Neurosci. 2021;12(1):581–600. PMID: 35070442; PMCID: PMC8724360. https://doi.org/10.1515/tnsci-2020-0206
52. Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47:529–42. PMID: 31477562; PMCID: PMC6796564. https://doi.org/10.1016/j.ebiom.2019.08.032
53. Staudacher HM, Black CJ, Teasdale SB, Mikocka-Walus A, Keefer L. Irritable bowel syndrome and mental health comorbidity—approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol. 2023;20(9):582–96. PMID: 37268741; PMCID: PMC10237074. https://doi.org/10.1038/s41575-023-00794-z
54. Richmond-Rakerd LS, D’Souza S, Milne BJ, Caspi A, Moffitt TE. Longitudinal Associations of Mental Disorders With Dementia: 30-Year Analysis of 1.7 Million New Zealand Citizens. JAMA Psychiatry. 2022;79(4):333–40. PMID: 35171209; PMCID: PMC8851362. https://doi.org/10.1001/jamapsychiatry.2021.4377
55. Richards EM, Li J, Stevens BR, Pepine CJ, Raizada MK. Gut Microbiome and Neuroinflammation in Hypertension. Circ Res. 2022;130(3):401–17. PMID: 35113664; PMCID: PMC8852773. https://doi.org/10.1161/CIRCRESAHA.121.319816
56. Tornkvist NT, Aziz I, Whitehead WE, Sperber AD, Palsson OS, Hreinsson JP, et al. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterol J. 2021;9(10):1178–88. PMID: 34599559; PMCID: PMC8672084. https://doi.org/10.1002/ueg2.12153
57. Bai C, Feng T, Huang N, Wang Q, Chen J, Zhao D, et al. The association between depression, anxiety, sleep disturbances and dementia: a prospective cohort study of 350,186 adults. BMC Neurol. 2026;26(1):105. PMID: 41612219; PMCID: PMC12903354. https://doi.org/10.1186/s12883-026-04676-0
58. Fond G, Loundou A, Hamdani N, Boukouaci W, Dargel A, Oliveira J, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651–60. PMID: 24705634. https://doi.org/10.1007/s00406-014-0502-z
59. Grover M, Kolla BP, Pamarthy R, Mansukhani MP, Breen-Lyles M, He JP, et al. Psychological, physical, and sleep comorbidities and functional impairment in irritable bowel syndrome: Results from a national survey of U.S. adults. PLoS One. 2021;16(1):e0245323. PMID: 33444383; PMCID: PMC7808669. https://doi.org/10.1371/journal.pone.0245323
60. Ungvari Z, Fekete M, Lehoczki A, Munkacsy G, Fekete JT, Zabo V, et al. Sleep disorders increase the risk of dementia, Alzheimer’s disease, and cognitive decline: a meta-analysis. Geroscience. 2025;47(3):4899–920. PMID: 40214959; PMCID: PMC12181552. https://doi.org/10.1007/s11357-025-01637-2
61. Fereshtehnejad SM, Lokk J. Healthcare Complexities in Neurodegenerative Proteinopathies: A Narrative Review. Healthcare (Basel). 2025;13(15). PMID: 40805906; PMCID: PMC12345698. https://doi.org/10.3390/healthcare13151873
62. Pellegrini C, Daniele S, Antonioli L, Benvenuti L, D’Antongiovanni V, Piccarducci R, et al. Prodromal Intestinal Events in Alzheimer’s Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. Int J Mol Sci. 2020;21(10). PMID: 32429301; PMCID: PMC7278916. https://doi.org/10.3390/ijms21103523
63. Zabihi S, Bestwick JP, Jitlal M, Bothongo PL, Zhang Q, Carter C, et al. Early presentations of dementia in a diverse population. Alzheimers Dement. 2025;21(2):e14578. PMID: 40008622; PMCID: PMC11863067. https://doi.org/10.1002/alz.14578
64. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6. PMID: 18436948; PMCID: PMC2335261. https://doi.org/10.1136/bmj.39489.470347.AD
65. Chiu RH, Lu SR, Liang FW, Lin CL, Ho CH, Hsiao PC. Risk of dementia in colorectal cancer patients receiving chemotherapy: A nationwide cohort study. Cancer Epidemiol. 2022;76:102083. PMID: 34920341. https://doi.org/10.1016/j.canep.2021.102083
66. Choi HG, Soh JS, Lim JS, Sim SY, Jung YJ, Lee SW. Peptic ulcer does not increase the risk of dementia: A nested case-control study using a national sample cohort. Medicine (Baltimore). 2020;99(33):e21703. PMID: 32872044; PMCID: PMC7437840. https://doi.org/10.1097/MD.0000000000021703
67. Kang DW, Lee JW, Park MY, Kim SH, Um YH, Wang SM, et al. Impact of Helicobacter pylori eradication on age-specific risk of incident dementia in patients with peptic ulcer disease: a nationwide population-based cohort study. Geroscience. 2025;47(1):1161–74. PMID: 39129052; PMCID: PMC11872846. https://doi.org/10.1007/s11357-024-01284-z
68. Momtaz YA, Hamid TA, Ibrahim R. Gastritis May Boost Odds of Dementia. Am J Alzheimers Dis Other Demen. 2014;29(5):452–6. PMID: 24408749; PMCID: PMC10852707. https://doi.org/10.1177/1533317513518654
69. Karantzoulis S, Galvin JE. Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother. 2011;11(11):1579–91. PMID: 22014137; PMCID: PMC3225285. https://doi.org/10.1586/ern.11.155
70. Kuate Defo A, Bakula V, Pisaturo A, Labos C, Wing SS, Daskalopoulou SS. Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis. Diabetes Obes Metab. 2024;26(2):441–62. PMID: 37869901. https://doi.org/10.1111/dom.15331
71. Zhang T, Zhang C, Zhang J, Sun F, Duan L. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front Cell Infect Microbiol. 2022;12:859967. PMID: 35433498; PMCID: PMC9010660. https://doi.org/10.3389/fcimb.2022.859967
72. Santiago JA, Potashkin JA. The Impact of Disease Comorbidities in Alzheimer’s Disease. Front Aging Neurosci. 2021;13:631770. PMID: 33643025; PMCID: PMC7906983. https://doi.org/10.3389/fnagi.2021.631770
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Nawris Alhassan, Mohamed Mohsen Helal, Jagdish Lal, Stanley Jung, Lisa Worsley